Two-year clinical outcomes of different drug-eluting stents with different polymer coating strategies in coronary artery heart disease: A multi-centre, randomised, controlled clinical trial

International Journal of Cardiology

Volumn 168, Issue 3, 2013, Pages 2646-2652

  Zhang, Yue ^a   Shen, Junle ^b   Li, Zhifeng ^a   Zhu, Aidong ^c   Yuan, Yuelong ^d   Yue, Ruihua ^b   Yuan, Jia ^a   Yin, Yuehui ^a   She, Qiang ^a   Chen, Yunqing ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b The Fourth People's Hospital of Chongqing   (China)

^c The Fifth People's Hospital of Chongqing   (China)

^d People's Hospital of Yongchuan   (China)

Author keywords

Coronary heart disease; Drug eluting stents; Major adverse cardiovascular events; Paclitaxel; Polymer; Rapamycin

Indexed keywords

ACETYLSALICYLIC ACID; BAYASPIRIN; BIOPOLYMER; CLOPIDOGREL; ENOXAPARIN; HEPARIN; PACLITAXEL; RAPAMYCIN; UNCLASSIFIED DRUG; WARFARIN; POLYMER;

AGED; ARTICLE; BIODEGRADABLE IMPLANT; CAUSE OF DEATH; CONTROLLED STUDY; DRUG COATING; DRUG ELUTING STENT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY DISEASE; PROSTHESIS; TIME;

AGED; CORONARY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; POLYMERS; PROSTHESIS DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885668966     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.03.034     Document Type: Article

References (36)

1. D.A. Jones, K.S. Rathod, and S. Gallagher Deployment of drug-eluting stents for isolated proximal LAD disease is associated with lower major adverse cardiac events (MACE) and no increase in stent thrombosis when compared to bare metal stents: a 5 year observational cohort study Catheter Cardiovasc Interv 81 6 2013 E237 E244
2. G.W. Stone, S.G. Ellis, and L. Cannon Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial JAMA 294 2005 1215 1223
3. W.F. Shen Evolution of interventional cardiology in China Chin Med J (Engl) 122 2009 2209 2219
4. W.F. Shen Interventional therapy of coronary artery disease in China: retrospective and perspective Chin Med J (Engl) 121 2008 2336 2341
5. M. Pfisterer, H.P. Brunner-La Rocca, and P.T. Buser Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 48 2006 2584 2591
6. X.C. Zhou, R.C. Huang, and B. Zhang Inflammation inhibitory effects of sirolimus and paclitaxel-eluting stents on interleukin-1β-induced coronary artery in-stent restenosis in pigs Chin Med J 123 2010 2405 2409
7. R. Wessely, J. Hausleiter, and C. Michaelis Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating Arterioscler Thromb Vasc Biol 25 2005 748 753
8. P. Buszman, S. Trznadel, and K. Milewski Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: a prospective multicenter registry Catheter Cardiovasc Interv 71 2008 51 57
9. J. Mehilli, R.A. Byrne, and A. Wieczorek Randomized trial of the three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis Eur Heart J 29 2008 1975 1982
10. J. Mehilli, A. Kastrati, and R. Wessely Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss Circulation 113 2006 273 279
11. R.A. Byrne, A. Kastrati, and S. Kufner Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stent (ISAR-TEST-4) Trial Eur Heart J 30 2009 2441 2449
12. L. Zhang, J. Yuan, and G. Liu One-year clinical outcome of a randomized trial of polymer-free paclitaxel-eluting stents versus biodegradable polymer-based rapamycin-eluting stents in patients with coronary heart disease J Interv Cardiol 25 2012 604 610
13. B. Xu, K.F. Dou, and Y.L. Han A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results Chin Med (Engl) 124 2011 811 816
14. Q.S. Zheng, R.Y. Sun, and Z.Y. Chen Sample size estimation and equivalence margin in noninferiority and equivalence trials Chin J New Drugs 12 2003 358 371
15. S.D. Wiviott, E. Braunwald, and C.H. McCabe Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomized trial Lancet 371 2008 1353 1363
16. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with Tirofiban in unstable angina and non-q-wave myocardial infarction N Engl J Med 338 1998 1488 1497
17. Y.X. Liu, C. Yao, F. Chen, Q.G. Chen, and B.H. Su Sample size estimation and statistical inference in noninferiority/equivalence trials Chin J Clin Pharmacol Ther 5 2000 344 348
18. J.W. van Werkum, A.A. Heestermans, and F.I. de Korte Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases Circulation 119 2009 828 834
19. J. Schofer, M. Schluter, and A.H. Gershlick Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS) Lancet 362 2003 1093 1099
20. E. Grube, S. Silber, and K.E. Hauptmann TAXUS I: six-and twelve-months results from a randomized double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions Circulation 107 2003 38 42
21. K. Tanabe, P.W. Serruys, and E. Grube TAXUS III trial: in-stent restenosis treated with stent based delivery of paclitaxel incorporated in a slow-release polymer formulation Circulation 107 2003 559 564
22. P.A. Lemos, P.W. Serruys, and R.T. van Domburg Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry Circulation 109 2004 190 195
23. K. Tanabe, P.W. Serruys, and M. Degertekin Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial Circulation 109 2004 196 200
24. E. Schampaert, E.A. Cohen, and M. Schluter The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS) J Am Coll Cardiol 43 2004 1110 1115
25. G.W. Stone, S.G. Ellis, and D.A. Cox One-year clinical results with the slow-release polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial Circulation 109 2004 1942 1947
26. H.B. Liu, B. Xu, and Y.J. Yang Long-term clinical outcomes after bioabsorbable polymer- and durable polymer-based sirolimus-eluting stents implantation: two-year follow-up results from a large single-center database Chin Med J (Engl) 122 2009 681 686
27. R. Virmani, G. Guagliumi, and A. Farb Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109 2004 701 705
28. R.A. Byrne, A. Kastrati, and K. Tiroch 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based cypher and endeavor, drug-eluting stents J Am Coll Cardiol 55 2010 2536 2543
29. S. Massberg, R.A. Byrne, and A. Kastrati Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting And Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-Eluting Stents (ISAR-TEST 5) Trial Circulation 124 2011 624 632
30. J.R. Costa, A. Abizaid, and R. Costa Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system JACC Cardiovasc Interv 1 2008 545 551
31. S. Dani, N. Kukreja, and P. Parikh Biodegradable-polymer-based, sirolimus-eluting Supralimus stents: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study EuroIntervention 4 2008 59 63
32. R.A. Byrne, S. Kufner, and K. Tiroch Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results Heart 95 2009 1489 1494
33. G. Denas, S. Padayattil Jose, and P. Gresele Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study J Thromb Thrombolysis 35 2013 178 184
34. G.N. Levine, E.R. Bates, and J.C. Blankenship 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122
35. K.W. Park, S.H. Kang, and H.M. Yang Impact of intravascular ultrasound guidance in routine percutaneous coronary intervention for conventional lesions: data from the EXCELLENT trial Int J Cardiol 167 3 Aug 10 2013 721 726
36. G.G. Stefanini, B. Kalesan, and P.W. Serruys Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomized non-inferiority trial Lancet 378 2011 1940 1948